Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Longton

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
The American Journal of Gastroenterology|November 6, 2001
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progressionB J Reid, L J Prevo, P C Galipeau, et al.
British Journal of Haematology|March 1, 1996
Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiationM E Flowers, J Zanis, R Pasquini, et al.
Blood|October 1, 1992
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexateR A Nash, M S Pepe, R Storb, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 1996
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recoveryK M Sullivan, J Storek, K J Kopecky, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
The American Journal of Gastroenterology|November 6, 2001
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progressionB J Reid, L J Prevo, P C Galipeau, et al.
British Journal of Haematology|March 1, 1996
Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiationM E Flowers, J Zanis, R Pasquini, et al.
Blood|October 1, 1992
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexateR A Nash, M S Pepe, R Storb, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 1996
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recoveryK M Sullivan, J Storek, K J Kopecky, et al.
Pageof 4